

Marta Toth,<sup>a</sup> Sergei B.  
Vakulenko<sup>a</sup> and Clyde A. Smith<sup>b\*</sup>

<sup>a</sup>Department of Chemistry and Biochemistry,  
University of Notre Dame, Notre Dame,  
IN 46556, USA, and <sup>b</sup>Stanford Synchrotron  
Radiation Light Source, Stanford University,  
Menlo Park, CA 94025, USA

Correspondence e-mail:  
csmith@slac.stanford.edu

Received 10 January 2012

Accepted 16 February 2012


## Purification, crystallization and preliminary X-ray analysis of the aminoglycoside-6'-acetyltransferase AAC(6')-Im

Bacterial resistance to the aminoglycoside antibiotics is primarily the result of enzymatic deactivation of the drugs. The aminoglycoside *N*-acetyltransferases (AACs) are a large family of bacterial enzymes that are responsible for coenzyme-A-facilitated acetylation of aminoglycosides. The gene encoding one of these enzymes, AAC(6')-Im, has been cloned and the protein (comprising 178 amino-acid residues) was expressed in *Escherichia coli*, purified and crystallized as the kanamycin complex. Synchrotron diffraction data to approximately 2.0 Å resolution were collected from a crystal of this complex on beamline BL12-2 at SSRL (Stanford, California, USA). The crystals belonged to the hexagonal space group  $P6_5$ , with approximate unit-cell parameters  $a = 107.75$ ,  $c = 37.33$  Å, and contained one molecule in the asymmetric unit. Structure determination is under way using molecular replacement.

### 1. Introduction

Ever since antimicrobial compounds were first used in a clinical setting to treat bacterial infections, there has been the concomitant emergence of bacterial strains that are resistant to these compounds. There are now bacterial isolates that are resistant to almost every antibacterial compound on the market, and such bacteria are increasingly causing life-threatening infections. One such family of antibacterials to which there is now universal widespread resistance are the aminoglycosides, which were originally isolated from soil bacteria (Greenwood, 1995). Streptomycin, the archetypal member of the aminoglycosides, was discovered in 1943 and was the first compound found to be effective against *Mycobacterium tuberculosis* (Greenwood, 1995). The aminoglycoside family, which includes a number of clinically relevant drugs such as gentamicin, tobramycin, kanamycin and amikacin, are targeted to the 30S ribosome, where drug binding leads to mistranslation of the mRNA (Carter *et al.*, 2000; Vakulenko & Mobashery, 2003).

Acquired resistance to the aminoglycosides primarily occurs through enzymatic modification of the drug and involves three different classes of enzyme, each with a number of variants. There are now 80 or more such bacterial enzymes; they are predominantly carried on mobile genetic elements, which facilitates their spread throughout both Gram-positive and Gram-negative bacterial populations. These enzymes fall into three classes: the coenzyme-A-dependent acetyltransferases (AACs) and the ATP-dependent nucleotidyltransferases (ANTs) and phosphotransferases (APHS) (Davies & Wright, 1997; Smith & Baker, 2002; Vakulenko & Mobashery, 2003; Kim & Mobashery, 2005; Ramirez & Tolmasky, 2010). They can be classified into subtypes according to the position on the drug at which the modification occurs and also according to their resistance profile, which specifies a subset of aminoglycosides that they are able to modify. Broad-spectrum resistance to the aminoglycosides in Gram-positive bacteria is dominated by the bifunctional enzyme AAC(6')-Ie-APH(2'')-Ia (Ferretti *et al.*, 1986) which comprises acetyltransferase and phosphotransferase functional domains and is the product of a single fused gene with a single start and stop codon. Despite this enzyme being the most important with respect to acquired resistance to the aminoglycosides, its structure has remained elusive to date. Difficulties in obtaining diffraction-quality crystals of the entire AAC(6')-Ie-APH(2'')-Ia may result from





beamline BL12-2 using a Pilatus 6M pixel array detector. A total of 650 images were collected with an oscillation angle of  $0.2^\circ$  and an exposure time of 0.2 s per image. The data were processed and scaled with the *XDS/XSCALE* programs (Kabsch, 2010). A summary of the data-collection statistics is given in Table 1. Preliminary molecular-replacement calculations were attempted using the programs *MOLREP* (Vagin & Teplyakov, 2010) and *Phaser* (McCoy *et al.*, 2007), utilizing the structure of AAC(6′)-Ib (Vetting *et al.*, 2008) as a search model.

### 3. Results and discussion

The AAC(6′)-Im enzyme was prepared either as the apo form or as the kanamycin complex, which proved to be very beneficial in that only the kanamycin–AAC(6′)-Im complex yielded diffraction-quality crystals. Four conditions gave crystals of the complex which diffracted to 2.0–2.7 Å resolution (Fig. 3): form I, 0.2 M potassium sodium tartrate, 0.1 M sodium citrate pH 5.6, 2.0 M ammonium sulfate; form II, 0.2 M MgCl<sub>2</sub>, 0.1 M Tris–HCl pH 8.5, 30% PEG 4000; form III,

**Table 1**


Statistics of native data collection.

Values in parentheses are for the highest resolution shell.

Wavelength (Å)	1.0332
Space group	<i>P</i> 6 <sub>5</sub>
Unit-cell parameters (Å)	<i>a</i> = 107.75, <i>c</i> = 37.33
Resolution range (Å)	35.3–2.0 (2.05–2.00)
Mosaicity (°)	0.5
Observed reflections	121419
Unique reflections	17083
Average multiplicity	7.1
<i>R</i> <sub>merge</sub> † (%)	6.7 (60.0)
<i>I</i> / <i>σ</i> ( <i>I</i> )	18.1 (3.9)
Completeness (%)	99.7 (97.1)


†  $R_{\text{merge}} = \frac{\sum_{hkl} \sum_i |I_i(hkl) - \langle I(hkl) \rangle|}{\sum_{hkl} \sum_i I_i(hkl)}$ , where  $I_i(hkl)$  is the observed intensity of a given reflection and  $\langle I(hkl) \rangle$  is the mean intensity for all observations of that reflection.

0.1 M MES pH 6.5, 12% PEG 20 000; form IV, 0.05 M HEPES pH 7.0, 20% PEG 3350, 1% tryptone. The form I crystals were block-like and required separation with a needle. Crystals of forms II, III and IV were all long thin needles which were readily separable and easily



**Figure 3**

The four crystal forms of AAC(6′)-Im: (a) form I crystals, (b) form II crystals, (c) form III crystals, (d) form IV crystals. The four panels are on the same scale; a scale bar is shown in (a).



**Figure 4** Diffraction image of the kanamycin complex of AAC(6')-Im, crystal form III. The resolution circle is at approximately 2.0 Å resolution.

mounted. Preliminary screening of the crystals showed that crystal forms I, II and III had different space groups and unit-cell parameters and that form IV was identical to form III. Form I crystals belonged to space group  $P2$  or  $P2_1$ , with unit-cell parameters  $a = 54.5$ ,  $b = 68.5$ ,  $c = 72.1$  Å,  $\beta = 106.8^\circ$ , and diffracted to approximately 2.7 Å resolution. Calculation of the Matthews coefficient ( $V_M$ ; Matthews, 1968) using an estimated molecular mass of 21.7 kDa gave a value of  $3.0 \text{ \AA}^3 \text{ Da}^{-1}$  (59% solvent content) assuming two molecules per asymmetric unit. Form II crystals belonged to space group  $C2$ , with unit-cell parameters  $a = 161.3$ ,  $b = 35.0$ ,  $c = 67.3$  Å,  $\beta = 102.6^\circ$ , and diffracted to around 2.1 Å resolution with two molecules in the asymmetric unit ( $V_M = 2.1 \text{ \AA}^3 \text{ Da}^{-1}$ ; 42% solvent content). Form III and IV crystals belonged to either a trigonal or hexagonal space group with either two molecules or one molecule in the asymmetric unit. The unit-cell parameters were approximately  $a = 107.8$ ,  $c = 37.3$  Å and the crystals diffracted to better than 2.0 Å resolution.

A single flash-cooled form III crystal in a cryoprotectant composed of the crystallization buffer with 20% glycerol was used to collect a complete X-ray data set. The crystal diffracted to approximately 1.9 Å resolution, but the high-resolution limit of the final data set was truncated at 2.0 Å because the value of  $R_{\text{merge}}$  in the 2.0–1.9 Å resolution shell was deemed to be too high at around 80%. A representative image is shown in Fig. 4 and the results are summarized in Table 1. Following data processing with *XDS* and *XSCALE*, the program *POINTLESS* (Evans, 2006) was used to determine the Laue group, resulting in two possible space groups:  $P6_1$  and  $P6_5$ . Calculation of the Matthews coefficient ( $V_M$ ) gave a value of  $2.9 \text{ \AA}^3 \text{ Da}^{-1}$  (57% solvent content) assuming one molecule per asymmetric unit.

Although the level of amino-acid sequence identity between the members of the AAC(6') subfamily is low, it was thought that molecular replacement using AAC(6')-Ib as a search model might give reasonable starting phases for the AAC(6')-Im structure. The

AAC(6')-Ib model was modified with the program *CHAINS*AW from the *CCP4* suite (Winn *et al.*, 2011), truncating the nonconserved residues at the  $C^\beta$  atom. Structural comparison of the three known AAC(6') structures [AAC(6')-Ib, PDB entry 1v0c (Vetting *et al.*, 2008); AAC(6')-Ii, PDB entry 1n71 (Burk *et al.*, 2003); AAC(6')-Iy, PDB entry 1s3z (Vetting *et al.*, 2004)] showed that although the main core of the molecule was structurally conserved, some of the surface loops had different lengths and adopted different conformations in the three models. Several different models were produced from this *CHAINS*AW model with loop truncations. Preliminary molecular-replacement calculations were performed using the programs *MOLREP* (Vagin & Teplyakov, 2010) and *Phaser* (McCoy *et al.*, 2007), testing the two possible hexagonal space groups suggested by *POINTLESS*; the best solution was obtained in space group  $P6_5$  by both programs. The  $R$  factor and score from *MOLREP* were 0.51 and 0.26, respectively, and the log-likelihood gain and  $Z$  score following the translation function from *Phaser* were 80 and 10.9, respectively. Refinement of the solution is currently being undertaken.

This work was supported by Grant No. AI057393 from the National Institutes of Health (SBV) and by Grant No. 5 P41 RR001209 from the National Center for Research Resources (SSRL). Portions of this research were carried out at the Stanford Synchrotron Radiation Laboratory, a national user facility operated by Stanford University on behalf of the US Department of Energy, Office of Basic Energy Sciences. The SSRL Structural Molecular Biology Program is supported by the Department of Energy (BES, BER) and by the National Institutes of Health (NCRR, BTP, NIGMS). The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.

## References

- Boehr, D. D., Daigle, D. M. & Wright, G. D. (2004). *Biochemistry*, **43**, 9846–9855.
- Burk, D. L., Ghuman, N., Wybenga-Groot, L. E. & Berghuis, A. M. (2003). *Protein Sci.* **12**, 426–437.
- Carter, A. P., Clemons, W. M., Brodersen, D. E., Morgan-Warren, R. J., Wimberly, B. T. & Ramakrishnan, V. (2000). *Nature (London)*, **407**, 340–348.
- Chow, J. W., Kak, V., You, I., Kao, S. J., Petrin, J., Clewell, D. B., Lerner, S. A., Miller, G. H. & Shaw, K. J. (2001). *Antimicrob. Agents Chemother.* **45**, 2691–2694.
- Cohen, A. E., Ellis, P. J., Miller, M. D., Deacon, A. M. & Phizackerley, R. P. (2002). *J. Appl. Cryst.* **35**, 720–726.
- Davies, J. & Wright, G. D. (1997). *Trends Microbiol.* **5**, 234–240.
- Evans, P. (2006). *Acta Cryst.* **D62**, 72–82.
- Ferretti, J. J., Gilmore, K. S. & Courvalin, P. (1986). *J. Bacteriol.* **167**, 631–638.
- Greenwood, D. (1995). *Antimicrobial Chemotherapy*, edited by D. Greenwood, pp. 32–48. Oxford University Press.
- Kabsch, W. (2010). *Acta Cryst.* **D66**, 125–132.
- Kim, C. & Mobashery, S. (2005). *Bioorg. Chem.* **33**, 149–158.
- Kim, C., Villegas-Estrada, A., Hesk, D. & Mobashery, S. (2007). *Biochemistry*, **46**, 5270–5282.
- Matthews, B. W. (1968). *J. Mol. Biol.* **33**, 491–497.
- McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). *J. Appl. Cryst.* **40**, 658–674.
- Ramirez, M. S. & Tolmasky, M. E. (2010). *Drug Resist. Updat.* **13**, 151–171.
- Smith, C. A. & Baker, E. N. (2002). *Curr. Drug Targets Infect. Dis.* **2**, 143–160.
- Vagin, A. & Teplyakov, A. (2010). *Acta Cryst.* **D66**, 22–25.
- Vakulenko, S. B. & Mobashery, S. (2003). *Clin. Microbiol. Rev.* **16**, 430–450.
- Vetting, M. W., Magnet, S., Nieves, E., Roderick, S. L. & Blanchard, J. S. (2004). *Chem. Biol.* **11**, 565–573.
- Vetting, M. W., Park, C. H., Hegde, S. S., Jacoby, G. A., Hooper, D. C. & Blanchard, J. S. (2008). *Biochemistry*, **47**, 9825–9835.
- Winn, M. D. *et al.* (2011). *Acta Cryst.* **D67**, 235–242.